IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ANDREOLI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.958
EU - Europa 7.217
AS - Asia 6.396
SA - Sud America 1.648
AF - Africa 155
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 17
AN - Antartide 1
Totale 27.413
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.770
SG - Singapore 2.250
DE - Germania 2.224
CN - Cina 1.815
BR - Brasile 1.393
UA - Ucraina 1.195
HK - Hong Kong 943
PL - Polonia 771
IT - Italia 759
RU - Federazione Russa 626
VN - Vietnam 506
FI - Finlandia 418
GB - Regno Unito 373
TR - Turchia 297
IE - Irlanda 235
FR - Francia 209
IN - India 126
AR - Argentina 99
BD - Bangladesh 96
CA - Canada 92
SE - Svezia 88
MX - Messico 64
ZA - Sudafrica 62
NL - Olanda 54
IQ - Iraq 50
EC - Ecuador 47
JP - Giappone 46
ES - Italia 40
ID - Indonesia 40
AT - Austria 37
CZ - Repubblica Ceca 28
PK - Pakistan 28
CO - Colombia 25
UZ - Uzbekistan 25
VE - Venezuela 25
MA - Marocco 23
SA - Arabia Saudita 23
EG - Egitto 22
AU - Australia 20
BE - Belgio 19
PY - Paraguay 18
JO - Giordania 16
AE - Emirati Arabi Uniti 15
CL - Cile 15
EU - Europa 15
CH - Svizzera 14
GR - Grecia 14
LT - Lituania 13
HR - Croazia 12
KE - Kenya 12
PE - Perù 12
IL - Israele 11
KZ - Kazakistan 11
MK - Macedonia 10
PH - Filippine 10
DK - Danimarca 9
PT - Portogallo 9
TH - Thailandia 9
DZ - Algeria 8
NP - Nepal 8
RS - Serbia 8
SK - Slovacchia (Repubblica Slovacca) 8
UY - Uruguay 8
HU - Ungheria 7
JM - Giamaica 7
AL - Albania 6
AZ - Azerbaigian 6
BG - Bulgaria 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
GE - Georgia 6
KR - Corea 6
RO - Romania 6
BH - Bahrain 5
BO - Bolivia 5
CR - Costa Rica 5
LB - Libano 5
LU - Lussemburgo 5
MY - Malesia 5
TN - Tunisia 5
IR - Iran 4
KH - Cambogia 4
KW - Kuwait 4
NO - Norvegia 4
PS - Palestinian Territory 4
SN - Senegal 4
AM - Armenia 3
BB - Barbados 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
LK - Sri Lanka 3
LV - Lettonia 3
OM - Oman 3
PA - Panama 3
SY - Repubblica araba siriana 3
HN - Honduras 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MD - Moldavia 2
Totale 27.386
Salva come PNG Salva come JPEG
Città #
Fairfield 1.489
Woodbridge 1.174
Singapore 1.038
Ashburn 998
Hong Kong 938
Jacksonville 830
Houston 826
Warsaw 763
Seattle 567
Cambridge 544
Wilmington 512
Ann Arbor 491
Beijing 448
Princeton 439
New York 360
Chandler 346
Helsinki 253
Istanbul 242
Dublin 235
Nanjing 226
The Dalles 224
Los Angeles 220
Ho Chi Minh City 169
Munich 149
São Paulo 135
Brescia 129
Dallas 117
Moscow 117
Redondo Beach 107
Hanoi 104
Nanchang 102
Nürnberg 102
San Diego 101
Des Moines 93
Buffalo 92
Changsha 85
Milan 81
Shanghai 78
Chicago 73
San Francisco 73
Shenyang 69
Hebei 65
Lancaster 62
London 57
Turku 52
Rio de Janeiro 50
Nuremberg 47
Santa Clara 45
Jinan 42
Tokyo 42
Johannesburg 36
Belo Horizonte 34
Tianjin 33
Dearborn 32
Jiaxing 32
Chennai 31
Toronto 31
Hangzhou 30
Denver 29
Atlanta 28
Poplar 28
Porto Alegre 28
Zhengzhou 28
Bergamo 27
Brooklyn 27
Curitiba 26
Guangzhou 25
Phoenix 25
Brasília 24
Dong Ket 24
Haiphong 24
Verona 24
Mexico City 23
Romola 23
Tashkent 23
Biên Hòa 22
Boardman 21
Dhaka 21
Kunming 21
Montreal 21
Orem 20
Da Nang 19
Brno 18
Brussels 18
Lanzhou 18
Guayaquil 17
Stockholm 17
Amman 16
Manchester 16
Taizhou 16
Amsterdam 15
Charlotte 15
Goiânia 15
Rome 15
Falkenstein 14
Frankfurt am Main 14
Haikou 14
Juiz de Fora 14
Ribeirão Preto 14
Ankara 13
Totale 16.720
Salva come PNG Salva come JPEG
Nome #
9A.07: CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS. ARE THERE ANY DIFFERENCES? 323
Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases. 281
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 273
The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation 237
Long-term outcome of children of rheumatic disease patients 217
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 216
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 214
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 199
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome 190
Antirheumatic drugs and reproduction in women and men with chronic arthritis. 190
The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus 187
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. 180
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 176
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends 175
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 175
Anti-phospholipid antibodies 174
Children born to SLE and APS mothers 172
A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus 172
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. 170
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 169
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 169
Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus. 168
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. 162
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus 162
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 160
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 158
25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. 157
Management of thrombotic and obstetric antiphospholipid syndrome: A systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults 157
Antiphospholipid antibodies mediate autoimmunity against dying cells. 156
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 154
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 152
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 151
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 151
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 149
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 149
Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome 147
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 147
Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis 147
Inflammatory molecules: A target for treatment of systemic autoimmune diseases. 146
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 146
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. 144
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7 144
Beyond the "syndrome": antiphospholipid antibodies as risk factors. 143
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes 143
State of the art: Reproduction and pregnancy in rheumatic diseases. 143
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 142
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. 142
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D 140
PROSPECTIVELY FOLLOWED PREGNANCIES IN PATIENTS WITH SYSTEMIC VASCULITIS: STILL MANY PROBLEMS ON BOTH FOETAL AND MATERNAL SIDE 139
Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 139
Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. 138
Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: Results from a multicenter study of 283 pregnancies 138
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? 137
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 137
Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. 136
Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 136
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 136
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al 136
ANTI-BETA2 GLYCOPROTEIN I-DOMAIN 1 AUTOANTIBODIES: COMPARISON BETWEEN TWO METHODS OF DETECTION 135
Management of recurrent thrombosis in antiphospholipid syndrome 135
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. 134
European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO) 134
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 134
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. 133
EFFICACY AND SAFETY OF CYCLOSPORINE-A DURING PREGNANCY IN AUTOIMMUNE DISEASES 133
Predictors of maternal and fetal complications in SLE patients: a prospective study 133
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 133
Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome 133
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 133
Pregnancy in patients with autoimmune disease: A reality in 2016 132
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 132
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? 131
Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. 131
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. 130
Neonatal effects of maternal antiphospholipid syndrome. 130
Long-term outcome of children born from mothers with autoimmune diseases 130
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases 129
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study 128
The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases 127
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. 126
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases 126
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy 125
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 124
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 123
Vitamin D and antiphospholipid syndrome. 122
DOMAIN 1 IS THE MAIN SPECIFICITY OF ANTI-BETA2GPI ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES 122
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 122
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 121
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 119
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 119
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 119
Subpopulations of anti-β₂glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β₂glycoprotein I 117
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study 117
Small extracellular vesicle-delivered microRNAs promote IFN-alpha secretion by plasmacytoid DCs via TLR7 116
A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP 115
The estimated frequency of Antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review 114
Pathophysiological role and therapeutic implications of vitamin d in autoimmunity: Focus on chronic autoimmune diseases 114
Anti-{beta}2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? 113
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study 113
Update on Antiphospholipid Syndrome: Ten Topics in 2017 112
Totale 14.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.836
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.836
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.181 0 0 0 0 0 422 113 354 331 473 312 176
2021/20221.763 114 280 54 102 20 102 57 132 103 206 172 421
2022/20231.285 248 16 32 58 125 377 5 107 176 4 65 72
2023/20241.814 108 64 144 158 66 345 56 78 456 33 26 280
2024/20254.520 84 71 66 530 408 411 509 247 392 351 915 536
2025/20265.837 856 1.383 744 1.497 911 446 0 0 0 0 0 0
Totale 27.862